H. Anne Pereira, Ph.D.

David L. Boren Professor/Dean, Graduate College

Pharmaceutical Sciences

Phone (405) 271-6593 x58034

Fax (405) 271-7505

Office CPB 329

Email anne-pereira@ouhsc.edu


Summary

My laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.



Research

This laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.



Patents

Biomarker and method for detecting a chronic inflammatory-associated disease

Patent No. 8,450,071

USA

H. Anne Pereira



Publications & Presentations

<< 7 8 9 10
    46. Pereira H A, Hosking C S. The role of complement and antibody in opsonization and intracellular killing of Candida albicans. Clinical and experimental immunology. 1984; 57 : 307-14

    47. Pereira H A, Shelton M J, Hosking C S. Neutrophil iodination micro-method as an index of neutrophil and opsonic function. Journal of clinical & laboratory immunology. 1983; 11 : 47-53

    48. Pereira H A, Hosking C S. Serum opsonins of control children of different ages. Australian paediatric journal. 1983; 19 : 23-6

<< 7 8 9 10



Grants

1 2 3 4 >>
    1. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2023. End Date: 2028.

    2. Vision Science Training Program. NIH. Start Date: 2021. End Date: 2026.

    3. STTR Phase 1: Multi-target Peptide Drug for Alzheimer's Disease. NIA. Start Date: 2024. End Date: 2025.

    4. STTR Phase 1: Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2023.

    5. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2018. End Date: 2023.

1 2 3 4 >>



Awards and Honors

<< 1 2 3 4 >>
                                                                                            11. American Heart Association. Established Investigator. Date: 1998.  

                                                                                            12. OUHSC. Provosts' Research Award to Junior Faculty. Date: 1994.  

                                                                                            13. American Lung Association. American Lung Association Research Award. Date: 1990.  

                                                                                            14. Gordon Research Conference on Phagocytes, New Hampshire. Travel Scholarship. Date: 1987.  

                                                                                            15. University of Melbourne, Australia. BSc (Honours) First Class Honours and First Place. Date: 1977.  

<< 1 2 3 4 >>



Education

                                                                                            1.  Degree: Ph D. University of Melbourne. Date: 1982.  

                                                                                            2.  Degree: BSc (Honours) First class honours & First Place. University of Melbourne. Date: 1976.  

                                                                                            3.  Degree: BS. University of Melbourne. Date: 1975.